ANZCTR search results

Phase 3 This sub-study is assessing the effects of the drug anastrozole on bone mineral density and other indicators on bone strength, when this drug is used to prevent breast cancer in postmenopausal women. This is an ANZ02P2/International Breast cancer Intervention Study: IBIS II Bone Sub-Protocol. Who is it for? You can join this trial if: You are joining the ANZ02P2 International Breast cancer Intervention Study: IBIS II (Prevention).You must not have not previously have had bilateral hip fractures or bilateral hip prostheses. You must not have a metabolic bone disease. You can not have regularly taken any medication affecting bone metabolism within the past 12 months unless you have been diagnosed as osteoporotic and are currently taking oral bisphosphonate (a bone strengthening drug). Trial details Participants will be divided into three groups based on the results of their baseline bone mineral density scans. Group 1 will comprise of participants with normal bone density. It will be recommended that these participants take calcium and vitamin D supplements. Group 2 will comprise of participants with osteopaenia (or reduced bone mineral density). These participants will be divided into two groups. One group will take the drug risedronate orally once a week for 5 years while the other group takes an inactive compound. It will be recommended that these participants also take calcium and vitamin D supplements. Group 3 consists of participants diagnosed with osteoporosis (low bone mineral density). These participants will take risedronate orally once a week for 5 years. All women in this sub-study (Groups 1, 2 and 3) will be monitored with bone mineral density scans. Risedronate is a type of drug called a bisphosphonate which acts to increase bone mass and strength.

Trial completed and published 2009 Flisberg P, Paech MJ, Shah T, Ledowski T, Kurowski I, Parsons R. Induction dose of propofgol in patients using cannabis. Euro J Anaesthesiol 2009;26:192-5

This study aims to determine whether the drug anastrozole can prevent breast cancer in postmenopausal women at increased risk of the disease. Who is it for? You may be eligible join this study if you are a postmenopausal woman aged 40-70 years and are at increased risk of breast cancer. In general terms increased risk is determined from family history, previous benign disease with evidence of proliferation, mammographic dysplasia, and childlessness (nulliparity). Trial details Participants in this trial will be randomly (by chance) allocated to one of two groups. Participants in one group will take one 1mg anastrozole tablet daily for 5 years. Participants in the other group will take a placebo (inactive) tablet daily for 5 years. Participants will be regularly assessed over the duration of the trial to determine whether anastrozole is effective in preventing breast cancer in postmenopausal women at increased risk of the disease.

CMV infection or reactivation causes morbidity and mortality in patients after allogeneic HSCT. We aim to adoptively transfer donor-derived CMV-specific CTL to prevent CMV infection and reactivation in these patients.

The trial completed in May 2005. A open lable clinical trial (TDMX) is an extension of this study.